Besides, the T2DM duration and T2DM medications that could reflect the glycemic levels such as DPP4 inhibitors and insulin did not alter the effect of SGLT2 inhibitors on corneal diseases development, which further support the universal protective effect of SGLT2 inhibitors on corneal disorders. This evidence concerns the gene SLC5A2 and corneal disorder.